GlassScriptPhysician profile
Sandra Mazzoni
NPI 1902218829
$34,977.99
in general payments reported to CMS, 2019-2025
19 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.66 · 2021: $67.25 · 2022: $157 · 2024: $11K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Honoraria: $4,446 · Food and Beverage: $2,809 · Travel and Lodging: $2,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,090.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,255.00 |
| Honoraria | $4,446.00 |
| Food and Beverage | $2,808.61 |
| Travel and Lodging | $2,140.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $7,796.53 | 2025 | |
| Janssen Scientific Affairs, LLC | $6,574.55 | 2022-2025 | Talvey, Darzalex, Tecvayli |
| Pfizer INC. | $6,104.16 | 2025 | |
| Janssen Biotech, INC. | $4,443.31 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $4,344.18 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $2,469.94 | 2024-2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $1,875.00 | 2025 | Ninlaro |
| Legend Biotech USA INC. | $400.53 | 2025 | Carvykti |
| Regeneron Healthcare Solutions, INC. | $144.37 | 2025 | Libtayo |
| Celgene Corporation | $143.67 | 2024 | Pomalyst |
| Janssen Research & Development, LLC | $130.21 | 2024-2025 | Talvey |
| Beone Medicines USA, INC. | $125.00 | 2025 | Brukinsa |
| Genzyme Corporation | $124.99 | 2025 | |
| Abbvie INC. | $79.80 | 2024 | |
| Sobi, INC | $66.98 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $53.07 | 2025 | Lynozyfic |
| Incyte Corporation | $45.74 | 2021-2024 | Jakafi |
| Rigel Pharmaceuticals, INC. | $42.30 | 2021 | |
| Dova Pharmaceuticals | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Mazzoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.